Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a leading global biotechnology company focused on discovering, developing, and delivering innovative human therapeutics. Specializing in treatments for serious illnesses, Amgen's key products include biologic medicines for cancer, kidney disease, and osteoporosis, contributing significantly to the advancement of healthcare.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Amgen has been active in the bond markets since 2001, with notable issuances such as its $1 billion senior notes in 2016, aimed at financing acquisitions and general corporate purposes. Recently, Amgen's bond yields have remained competitive within the biotechnology sector, currently ranging around 3.5%, which reflects investor confidence in its strong cash flow and robust product pipeline. Noteworthy features of its bond offerings include callable options, providing the company flexibility in managing debt in a fluctuating interest rate environment.